EOSINOPHILS, APOPTOSIS, AND ASTHMA

嗜酸性粒细胞、细胞凋亡和哮喘

基本信息

  • 批准号:
    6612399
  • 负责人:
  • 金额:
    $ 24.21万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2002
  • 资助国家:
    美国
  • 起止时间:
    2002-07-01 至 2003-06-30
  • 项目状态:
    已结题

项目摘要

Eosinophils are the most abundant and injurious of the effector cells of asthma where there is evidence for their enhanced differentiation and release from bone marrow; recruitment, activation and prolonged survival. It is hypothesized that eosinophil longevity in the asthmatic airway contributes to eosinophil accumulation and capacity to damage the asthmatic airway via production of inflammatory mediators, cytokines, reactive oxygen species, and most importantly, the eosinophilic cationic proteins which lead to the airway hyperreactivity Resolution of asthmatic eosinophilic inflammation requires eosinophil apoptosis and removal, and it is the objective of this proposal to determine the mechanisms by which apoptosis occurs. Apoptotic eosinophils are seen more often in the asthmatic airway lumen than tissue, and it is the objective of this proposal to determine the mechanisms by which apoptosis occurs. Apoptotic eosinophils are seen more often in the asthmatic airway lumen than tissue, and it is hypothesized that this can be explained by three factors: loss of pro- survival cytokine stimulation in the airway lumen; the presence of pro- apoptotic factors at this site; and inefficient clearance by phagocytes in the airway lumen, relative to tissue. While the importance of pro- survival signaling by the HSFs has been investigated, little is known of integrated signaling from the interplay or "mix" of pro-survival (HSFs, integrins, chemotactic factors) and pro-apoptotic signaling (Fas, TNF- alpha, oxidant generation, corticosteroids), which are expected to occur in vivo. From preliminary data, it is hypothesized that constitutive apoptosis is driven by oxidant production from mitochondria, and that responses to "mixed" signaling are determined by oxidant generation, mitochondrial protection by MnSOD, and autocrine production of survival factors. Furthermore, while signaling via NFkappaB, Akt and ERK are thought to be redundant in HSF pro-survival signaling, it is hypothesized that these pathways become critical for survival during "mixed" signaling . These pathways are also expected to determine eosinophil response during corticosteroid treatment where inhibition of NFkappaB results in loss of MnSOD protection of mitochondria, apoptosis and rapid secondary cytolysis (with release of cationic proteins to the tissues). Conversely, pro-apoptosis and rapid secondary cytolysis (with release of cationic proteins to the tissues). Conversely, pro-survival signaling leads to MnSOD expression and mitochondrial protection which results in eosinophil insensitivity to corticosteroids. These hypothesis will be investigated both in vitro in isolated eosinophils, and in vivo using the murine allergen challenge model of airway hyperreactivity and in human allergic asthma. Findings are expected to broaden our understanding of eosinophil longevity and offer new insights into potential therapeutic targets.
嗜酸性粒细胞是最丰富和最有害的哮喘效应细胞,其中有证据表明其增强的分化和从骨髓中释放;募集,活化和延长存活。假设嗜酸性粒细胞在哮喘气道中的寿命有助于嗜酸性粒细胞的积累和通过产生炎性介质、细胞因子、活性氧物质以及最重要的是导致气道高反应性的嗜酸性阳离子蛋白来损害哮喘气道的能力。哮喘嗜酸性粒细胞炎症的解决需要嗜酸性粒细胞凋亡和去除,并且该建议的目的是确定细胞凋亡发生的机制。凋亡的嗜酸性粒细胞在哮喘气道腔中比在组织中更常见,本研究的目的是确定凋亡发生的机制。凋亡的嗜酸性粒细胞在哮喘气道腔中比在组织中更常见,并且假设这可以由三个因素解释:气道腔中促存活细胞因子刺激的丧失;在该部位存在促凋亡因子;以及相对于组织,气道腔中吞噬细胞的清除效率低下.虽然已经研究了HSF促存活信号传导的重要性,但是对于来自促存活(HSF、整联蛋白、趋化因子)和促凋亡信号传导(Fas、TNF-α、氧化剂生成、皮质类固醇)的相互作用或“混合”的整合信号传导知之甚少,预期其在体内发生。从初步的数据,它是假设,组成性细胞凋亡是由线粒体的氧化剂生产,并确定了“混合”信号的响应由氧化剂的产生,线粒体保护MnSOD,和自分泌生产的生存因子。此外,虽然认为经由NF κ B、Akt和ERK的信号传导在HSF促存活信号传导中是冗余的,但假设这些途径在“混合”信号传导期间对于存活变得至关重要。预期这些途径还可确定皮质类固醇治疗期间的嗜酸性粒细胞反应,其中NF κ B的抑制导致线粒体MnSOD保护的丧失、细胞凋亡和快速继发性细胞溶解(伴随阳离子蛋白质向组织的释放)。相反,促细胞凋亡和快速继发性细胞溶解(释放阳离子蛋白到组织)。相反,促存活信号传导导致MnSOD表达和线粒体保护,这导致嗜酸性粒细胞对皮质类固醇不敏感。这些假设将在分离的嗜酸性粒细胞中进行体外研究,并在体内使用气道高反应性的鼠变应原激发模型和人过敏性哮喘中进行研究。研究结果有望拓宽我们对嗜酸性粒细胞寿命的理解,并为潜在的治疗靶点提供新的见解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DONNA L BRATTON其他文献

DONNA L BRATTON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DONNA L BRATTON', 18)}}的其他基金

Neutrophil Nox2 controls mononuclear cell functions in inflammation; role in CGD
中性粒细胞 Nox2 控制炎症中的单核细胞功能;
  • 批准号:
    10456072
  • 财政年份:
    2018
  • 资助金额:
    $ 24.21万
  • 项目类别:
Neutrophil Nox2 controls mononuclear cell functions in inflammation; role in CGD
中性粒细胞 Nox2 控制炎症中的单核细胞功能;
  • 批准号:
    10228694
  • 财政年份:
    2018
  • 资助金额:
    $ 24.21万
  • 项目类别:
Reversal of Inflammatory Processes in CGD
CGD 中炎症过程的逆转
  • 批准号:
    9416907
  • 财政年份:
    2014
  • 资助金额:
    $ 24.21万
  • 项目类别:
Reversal of Inflammatory Processes in CGD
CGD 中炎症过程的逆转
  • 批准号:
    8803304
  • 财政年份:
    2014
  • 资助金额:
    $ 24.21万
  • 项目类别:
Reversal of Inflammatory Processes in CGD
CGD 中炎症过程的逆转
  • 批准号:
    8669607
  • 财政年份:
    2014
  • 资助金额:
    $ 24.21万
  • 项目类别:
Cell Cuture Core
细胞培养核心
  • 批准号:
    8053034
  • 财政年份:
    2011
  • 资助金额:
    $ 24.21万
  • 项目类别:
Lyso-PS and resolution of acute lung inflammation
Lyso-PS 和急性肺部炎症的解决
  • 批准号:
    8053030
  • 财政年份:
    2011
  • 资助金额:
    $ 24.21万
  • 项目类别:
Macrophage PPARg signaling, efferocytosis, and exaggerated inflammation in CGD
CGD 中的巨噬细胞 PPARg 信号传导、胞吞作用和过度炎症
  • 批准号:
    8299285
  • 财政年份:
    2011
  • 资助金额:
    $ 24.21万
  • 项目类别:
Cell Culture Core
细胞培养核心
  • 批准号:
    7142913
  • 财政年份:
    2005
  • 资助金额:
    $ 24.21万
  • 项目类别:
Phospholipid signaling from apoptotic cells
来自凋亡细胞的磷脂信号传导
  • 批准号:
    7142871
  • 财政年份:
    2005
  • 资助金额:
    $ 24.21万
  • 项目类别:

相似海外基金

Defining new asthma phenotypes using high-dimensional data
使用高维数据定义新的哮喘表型
  • 批准号:
    2901112
  • 财政年份:
    2024
  • 资助金额:
    $ 24.21万
  • 项目类别:
    Studentship
Basophilic oncostatin M fuels nociceptor neuron-induced asthma
嗜碱性制瘤素 M 促进伤害感受器神经元诱发哮喘
  • 批准号:
    485504
  • 财政年份:
    2023
  • 资助金额:
    $ 24.21万
  • 项目类别:
    Salary Programs
Engaging Patient and Caregivers in Using Patient-reported Outcomes Measures in Pediatric Clinical Care for Asthma
让患者和护理人员参与儿科哮喘儿科临床护理中患者报告的结果测量
  • 批准号:
    495593
  • 财政年份:
    2023
  • 资助金额:
    $ 24.21万
  • 项目类别:
Air pollution and Asthma in Canada: Projections of burden and the value of climate adaptation strategies
加拿大的空气污染和哮喘:负担预测和气候适应战略的价值
  • 批准号:
    485322
  • 财政年份:
    2023
  • 资助金额:
    $ 24.21万
  • 项目类别:
    Operating Grants
Data-driven model links BMIz to gene expression in pediatric asthma
数据驱动模型将 BMIz 与小儿哮喘基因表达联系起来
  • 批准号:
    493135
  • 财政年份:
    2023
  • 资助金额:
    $ 24.21万
  • 项目类别:
BIOlogic drug safety and effectiveness interNational pharmacoepidemiologIC study in pregnant women with autoimmune disorders and asthma and their children (BIONIC)
患有自身免疫性疾病和哮喘的孕妇及其子女的生物药物安全性和有效性国际药物流行病学研究(BIONIC)
  • 批准号:
    493526
  • 财政年份:
    2023
  • 资助金额:
    $ 24.21万
  • 项目类别:
    Operating Grants
A Novel Approach to Target Neutrophilic Airway Inflammation and Airway Hyperresponsiveness in Therapy-Resistant (Refractory) Asthma.
一种针对难治性哮喘中性粒细胞性气道炎症和气道高反应性的新方法。
  • 批准号:
    10659658
  • 财政年份:
    2023
  • 资助金额:
    $ 24.21万
  • 项目类别:
Treating Maternal Depression in an Urban Community-Based Pediatric Asthma Clinic: Targeting Maternal Mood, Child Asthma Outcomes, and Health Disparities
在城市社区小儿哮喘诊所治疗孕产妇抑郁症:针对孕产妇情绪、儿童哮喘结果和健康差异
  • 批准号:
    10723233
  • 财政年份:
    2023
  • 资助金额:
    $ 24.21万
  • 项目类别:
Improving Prediction of Asthma-related Outcomes with Genetic Ancestry-informed Lung Function Equations
利用遗传祖先信息的肺功能方程改善哮喘相关结果的预测
  • 批准号:
    10723861
  • 财政年份:
    2023
  • 资助金额:
    $ 24.21万
  • 项目类别:
Prenatal Fatty Acid Supplementation and Early Childhood Asthma and Atopy in Black American Families
美国黑人家庭产前脂肪酸补充剂与儿童早期哮喘和特应性
  • 批准号:
    10586398
  • 财政年份:
    2023
  • 资助金额:
    $ 24.21万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了